Skip to main content

Kissei Pharmaceutical Co., Ltd. (KSPHF)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
63.4Fair

ValueMarkers Composite Index

Top 90%#4,659 of 44,722

DCF data not available

Piotroski
6/9
Neutral
Beneish
-2.44
Low Risk
Altman
1.66
Distress
DCF Value
-
N/A
ROIC
-0.7%
Low
P/E
13.8
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Kissei Pharmaceutical Co., Ltd. (KSPHF) — VMCI valuation read

Kissei Pharmaceutical Co., Ltd. (KSPHF) carries a VMCI composite of 63/100, 13 points above the Healthcare sector median of 50. Among mid-cap names, that gap places KSPHF in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The KSPHF insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads KSPHF trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.7x is the rate-sensitivity line to watch, the line to track on Kissei Pharmaceutical Co., Ltd.'s next 10-Q.

KSPHF fell 3.2% over the trailing 7 days, with a -21.6% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.